Bullous pemphigoid / pemphigoid

• (2026): Patil RC+, J Pharm Bioallied Sci 18(Suppl 1), S260-S262 (1 case / female)

Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))

• (2023): Rizzi A+, Asian Pac J Allergy Immunol Oct, Online ahead of print [REVIEW]
• (2022): Modi B+, Indian J Tuberc 69(4), 470-475 (56 cases)

DRESS syndrome (Drug-induced hypersensitivity syndrome / DIHS)

• (2025): Lagrutta L+, Medicina (B Aires) (Spanish) 85(3), 572-585 [REVIEW]
• (2024): Bouhamdi A+, Dermatol Online J Dec, Online ahead of print (1 case / male)

Hypersensitivity

• (2025): Katran ZY+, Allergol Immunopathol (Madr) 53(5), 69-7712% [REVIEW] (risk factors)
• (2025): Liu Q+, Br J Clin Pharmacol 91(1), 134-1423%

Lesions (includes skin lesions)

• (2025): Pavlović MD+, Acta Dermatovenerol Alp Pannonica Adriat 34(2), 85-87 (1 case / female) (paradoxical reaction)

Skin (dermatological) reaction

Alanine aminotransferase (ALT) increased

• (2024): Chen X+, J Clin Pharmacol Mar, Online ahead of print

Hypothyroidism

• (2024): Quiroz-Aldave JE+, Expert Rev Endocrinol Metab Jan, Online ahead of print17% [REVIEW]

Metabolic syndrome (includes metabolic disorder)

• (2023): Lim J+, Open Forum Infect Dis Aug (e-Collection) (association)

Gastrointestinal disorder / discomfort

• (2018): Fei CM+, Malays J Med Sci 25(5), 1035% [REVIEW]

Hepatitis

• (2025): Noviansyah EI+, Int J Mycobacteriol 14(3), 219-22527%
• (2020): Gezahegn LK+, PLoS One 15(11), e024134614%

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

• (2026): Prasad S+, JGH Open Jan (e-Collection) [REVIEW]
• (2025): Chen R+, J Gastrointestin Liver Dis 34(1), 55-63 (pharmacogenomics)
• (2025): Cheng J+, Int J Clin Pharm Feb, Online ahead of print [REVIEW] (pharmacogenomics)
• (2025): de Los Santos-Fernández RL+, Br J Clin Pharmacol 91(6), 1660-1674 [REVIEW] (pharmacogenomics)
• (2025): Han B+, Pak J Pharm Sci 38(3), 751-758
• (2025): Klindt C+, Infection Sep, Online ahead of print16% (severe 4%) (risk factors)
• (2025): Manokaran V+, Cureus 17(6), e8566132% (underlying risk factors)
• (2025): Zhang S+, Infect Drug Resist 18, 2065-2078 [REVIEW]
• (2024): He Q+, Br J Clin Pharmacol Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
• (2023): Akkahadsee P+, Sci Rep 13(1), 19880 [REVIEW]
• (2022): Jaramillo-Valverde L+, Mol Genet Genomic Med Jun, Online ahead of print (pharmacogenomics)
• (2022): Jaramillo-Valverde L+, Int J Mol Sci 23 (19), 11028 (pharmacogenomics)
• (2021): Becker MW+, World J Gastrointest Pharmacol Ther 12(3), 40-55 [REVIEW]
• (2021): Chanhom N+, Heliyon 7(4), e06852
• (2021): Huang YS+, J Chin Med Assoc Oct, Online ahead of print25%
• (2021): Jiang F+, Liver Int Apr, Online ahead of print5%
• (2021): Khiewkhern S+, Stud Health Technol Inform 281, 784-7886%
• (2021): Nataprawira HM+, Am J Case Rep 22, e930828 (6 cases)
• (2021): Zhu J+, J Clin Pharm Ther May, Online ahead of print
• (2020): Kumar PS+, EJIFCC 31(3), 242-247 (1 case / female)
• (2020): Radhika S+, Curr Drug Saf Jun, Online ahead of print14%
• (2020): Xu N+, Eur J Hosp Pharm Sep, Online ahead of print4%
• (2020): Yang M+, Pharmacol Res Perspect 8(6), e00696 [REVIEW]
• (2020): Zeleke A+, BMC Res Notes 13(1), 220%

Thrombocytopenia / platelets decreased

• (2023): Kaur A+, Indian J Tuberc 70(4), 489-496 [REVIEW]

Adverse effects / adverse reactions

• (2021): Trubnikov A+, Int J Environ Res Public Health 18(8) [REVIEW]